Actively Recruiting

Phase Not Applicable
Age: 40Years +
All Genders
NCT06614959

The Effects of Oscillatory Positive Expiratory Pressure (OPEP) Therapy in Patients With COPD

Led by McGill University Health Centre/Research Institute of the McGill University Health Centre · Updated on 2025-05-28

32

Participants Needed

1

Research Sites

70 weeks

Total Duration

On this page

Sponsors

M

McGill University Health Centre/Research Institute of the McGill University Health Centre

Lead Sponsor

T

Trudell Medical International

Collaborating Sponsor

AI-Summary

What this Trial Is About

The goal of this non-pharmacologic interventional study is to learn if Oscillatory Positive Expiratory Pressure (OPEP) therapy can improve disease impact and respiratory system dynamics in patients with COPD. The main questions it aims to answer are: Is OPEP therapy able to improve the impact of cough symptoms as measured on a validated symptom score? Is OPEP therapy able to improve the properties of the lung (called reactance) as measured by oscillometry? Researchers will compare the results of the same tests performed before and after 4 weeks of OPEP treatment to see if OPEP treatment improves cough symptoms and lung mechanics. * Participants with COPD will complete in-person baseline tests and will then receive the smart OPEP device. * These participants will then use the smart OPEP device at home, at least twice a day, for 4 consecutive weeks. * Finally, these participants will return to complete in-person end-of-study tests.

CONDITIONS

Official Title

The Effects of Oscillatory Positive Expiratory Pressure (OPEP) Therapy in Patients With COPD

Who Can Participate

Age: 40Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Males and females 40 years of age or more
  • Former or current smokers with a cigarette smoking history of 10 or more pack-years
  • Physician diagnosis of COPD confirmed by spirometry with FEV1/FVC less than 0.7, ranging from mild to very severe (GOLD 1-4)
  • Chronic bronchitis phenotype defined by sputum production or productive cough more than 2 days per week for the last 3 months for at least 2 consecutive years, or cough and phlegm almost every day or several times per week
  • Ability to participate in oscillometry testing without supplemental oxygen
  • Ability to provide informed consent
Not Eligible

You will not qualify if you...

  • No diagnosis of COPD
  • Bronchiectasis, cystic fibrosis, or other known chronic suppurative lung disease as the main respiratory condition
  • Exacerbation or hospitalization for lung symptoms in the 4 weeks before baseline testing
  • Current use of OPEP or use of OPEP within 4 weeks before baseline
  • Current or recent participation in a standard Pulmonary Rehabilitation program within 4 weeks before baseline or during the study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

McGill University Health Centre

Montreal, Quebec, Canada, H4A 3J1

Actively Recruiting

Loading map...

Research Team

B

Bryan A. Ross, MD, MSc (Physiol), MSc (Epi)

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here